NZ271617A - Oral pharmaceutical composition comprising micronized progesterone, poly ethylene glycol and a starch, cellulose pectin or tragacanth excipient - Google Patents
Oral pharmaceutical composition comprising micronized progesterone, poly ethylene glycol and a starch, cellulose pectin or tragacanth excipientInfo
- Publication number
- NZ271617A NZ271617A NZ271617A NZ27161794A NZ271617A NZ 271617 A NZ271617 A NZ 271617A NZ 271617 A NZ271617 A NZ 271617A NZ 27161794 A NZ27161794 A NZ 27161794A NZ 271617 A NZ271617 A NZ 271617A
- Authority
- NZ
- New Zealand
- Prior art keywords
- starch
- progesterone
- pharmaceutical composition
- composition according
- estradiol
- Prior art date
Links
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 title claims description 142
- 229920002472 Starch Polymers 0.000 title claims description 46
- 235000019698 starch Nutrition 0.000 title claims description 41
- 239000008107 starch Substances 0.000 title claims description 38
- 239000000546 pharmaceutical excipient Substances 0.000 title claims description 18
- 229920002678 cellulose Polymers 0.000 title claims description 16
- 235000010980 cellulose Nutrition 0.000 title claims description 16
- 239000001913 cellulose Substances 0.000 title claims description 14
- 229920001223 polyethylene glycol Polymers 0.000 title claims description 14
- 239000002202 Polyethylene glycol Substances 0.000 title claims description 10
- 241000416162 Astragalus gummifer Species 0.000 title claims description 6
- 229920001615 Tragacanth Polymers 0.000 title claims description 6
- 229960001207 micronized progesterone Drugs 0.000 title claims description 6
- 239000001814 pectin Substances 0.000 title claims description 6
- 235000010987 pectin Nutrition 0.000 title claims description 6
- 229920001277 pectin Polymers 0.000 title claims description 6
- 235000010487 tragacanth Nutrition 0.000 title claims description 6
- 239000000196 tragacanth Substances 0.000 title claims description 6
- 229940116362 tragacanth Drugs 0.000 title claims description 6
- 239000008203 oral pharmaceutical composition Substances 0.000 title 1
- 229960003387 progesterone Drugs 0.000 claims description 67
- 239000000186 progesterone Substances 0.000 claims description 67
- 239000000203 mixture Substances 0.000 claims description 36
- 239000008194 pharmaceutical composition Substances 0.000 claims description 24
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 claims description 22
- 229960005309 estradiol Drugs 0.000 claims description 22
- 229930182833 estradiol Natural products 0.000 claims description 21
- 229920002261 Corn starch Polymers 0.000 claims description 14
- 235000019759 Maize starch Nutrition 0.000 claims description 13
- 229920000881 Modified starch Polymers 0.000 claims description 9
- 235000019426 modified starch Nutrition 0.000 claims description 9
- 239000004368 Modified starch Substances 0.000 claims description 8
- 239000008187 granular material Substances 0.000 claims description 8
- 229920001592 potato starch Polymers 0.000 claims description 8
- 238000009472 formulation Methods 0.000 claims description 7
- 239000011230 binding agent Substances 0.000 claims description 6
- 238000002156 mixing Methods 0.000 claims description 6
- 229940100486 rice starch Drugs 0.000 claims description 6
- 229920000945 Amylopectin Polymers 0.000 claims description 5
- 229920000856 Amylose Polymers 0.000 claims description 5
- 239000002775 capsule Substances 0.000 claims description 5
- 239000000314 lubricant Substances 0.000 claims description 5
- 229940100445 wheat starch Drugs 0.000 claims description 5
- 229940116317 potato starch Drugs 0.000 claims description 4
- -1 rice starch Polymers 0.000 claims description 4
- 210000002966 serum Anatomy 0.000 claims description 4
- 240000003183 Manihot esculenta Species 0.000 claims description 3
- 235000016735 Manihot esculenta subsp esculenta Nutrition 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 238000000034 method Methods 0.000 claims description 3
- 230000036470 plasma concentration Effects 0.000 claims 1
- 239000003826 tablet Substances 0.000 description 40
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 9
- 239000007884 disintegrant Substances 0.000 description 8
- 239000000306 component Substances 0.000 description 7
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 6
- 230000007812 deficiency Effects 0.000 description 6
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 description 6
- 239000008101 lactose Substances 0.000 description 6
- 235000019359 magnesium stearate Nutrition 0.000 description 6
- 229920002785 Croscarmellose sodium Polymers 0.000 description 5
- 150000001875 compounds Chemical class 0.000 description 5
- 239000000003 vaginal tablet Substances 0.000 description 5
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- 238000010521 absorption reaction Methods 0.000 description 4
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 4
- 229960001681 croscarmellose sodium Drugs 0.000 description 4
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 4
- 239000002245 particle Substances 0.000 description 4
- 229940093429 polyethylene glycol 6000 Drugs 0.000 description 4
- 229920000642 polymer Polymers 0.000 description 4
- 239000001828 Gelatine Substances 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 230000002349 favourable effect Effects 0.000 description 3
- 229920000159 gelatin Polymers 0.000 description 3
- 235000019322 gelatine Nutrition 0.000 description 3
- 238000002657 hormone replacement therapy Methods 0.000 description 3
- 230000035935 pregnancy Effects 0.000 description 3
- 239000000583 progesterone congener Substances 0.000 description 3
- 239000007916 tablet composition Substances 0.000 description 3
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- DNXHEGUUPJUMQT-CBZIJGRNSA-N Estrone Chemical compound OC1=CC=C2[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1 DNXHEGUUPJUMQT-CBZIJGRNSA-N 0.000 description 2
- 208000032843 Hemorrhage Diseases 0.000 description 2
- 235000021355 Stearic acid Nutrition 0.000 description 2
- 206010047486 Virilism Diseases 0.000 description 2
- VJHCJDRQFCCTHL-UHFFFAOYSA-N acetic acid 2,3,4,5,6-pentahydroxyhexanal Chemical compound CC(O)=O.OCC(O)C(O)C(O)C(O)C=O VJHCJDRQFCCTHL-UHFFFAOYSA-N 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 230000000740 bleeding effect Effects 0.000 description 2
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 210000004696 endometrium Anatomy 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 2
- 229940127234 oral contraceptive Drugs 0.000 description 2
- 239000003539 oral contraceptive agent Substances 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 239000000377 silicon dioxide Substances 0.000 description 2
- 239000008117 stearic acid Substances 0.000 description 2
- 229940044977 vaginal tablet Drugs 0.000 description 2
- VOXZDWNPVJITMN-QXDIGNSFSA-N (8s,9r,13r,14r,17r)-13-methyl-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthrene-3,17-diol Chemical compound OC1=CC=C2[C@@H]3CC[C@@](C)([C@@H](CC4)O)[C@H]4[C@H]3CCC2=C1 VOXZDWNPVJITMN-QXDIGNSFSA-N 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 201000000736 Amenorrhea Diseases 0.000 description 1
- 206010001928 Amenorrhoea Diseases 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 206010013908 Dysfunctional uterine bleeding Diseases 0.000 description 1
- 102000002322 Egg Proteins Human genes 0.000 description 1
- 108010000912 Egg Proteins Proteins 0.000 description 1
- 201000009273 Endometriosis Diseases 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 229920003083 Kollidon® VA64 Polymers 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 206010027514 Metrorrhagia Diseases 0.000 description 1
- 206010067572 Oestrogenic effect Diseases 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 239000008118 PEG 6000 Substances 0.000 description 1
- 229920002584 Polyethylene Glycol 6000 Polymers 0.000 description 1
- 244000061456 Solanum tuberosum Species 0.000 description 1
- 235000002595 Solanum tuberosum Nutrition 0.000 description 1
- 241000209140 Triticum Species 0.000 description 1
- 235000021307 Triticum Nutrition 0.000 description 1
- 238000010306 acid treatment Methods 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 230000029936 alkylation Effects 0.000 description 1
- 238000005804 alkylation reaction Methods 0.000 description 1
- WQZGKKKJIJFFOK-UHFFFAOYSA-N alpha-D-glucopyranose Natural products OCC1OC(O)C(O)C(O)C1O WQZGKKKJIJFFOK-UHFFFAOYSA-N 0.000 description 1
- 231100000540 amenorrhea Toxicity 0.000 description 1
- 230000001548 androgenic effect Effects 0.000 description 1
- 230000001833 anti-estrogenic effect Effects 0.000 description 1
- 230000002513 anti-ovulatory effect Effects 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 229940105329 carboxymethylcellulose Drugs 0.000 description 1
- 229950008138 carmellose Drugs 0.000 description 1
- 238000007385 chemical modification Methods 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 239000003433 contraceptive agent Substances 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 229960005168 croscarmellose Drugs 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 239000001767 crosslinked sodium carboxy methyl cellulose Substances 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 150000002009 diols Chemical class 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 230000002357 endometrial effect Effects 0.000 description 1
- 230000001076 estrogenic effect Effects 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 230000004720 fertilization Effects 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 230000010224 hepatic metabolism Effects 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 239000003701 inert diluent Substances 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 208000000509 infertility Diseases 0.000 description 1
- 231100000535 infertility Toxicity 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000029849 luteinization Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 230000011599 ovarian follicle development Effects 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 210000004681 ovum Anatomy 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 229950010765 pivalate Drugs 0.000 description 1
- IUGYQRQAERSCNH-UHFFFAOYSA-N pivalic acid Chemical compound CC(C)(C)C(O)=O IUGYQRQAERSCNH-UHFFFAOYSA-N 0.000 description 1
- 229920000191 poly(N-vinyl pyrrolidone) Polymers 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 229940096331 progesterone 100 mg Drugs 0.000 description 1
- RJKFOVLPORLFTN-UHFFFAOYSA-N progesterone acetate Natural products C1CC2=CC(=O)CCC2(C)C2C1C1CCC(C(=O)C)C1(C)CC2 RJKFOVLPORLFTN-UHFFFAOYSA-N 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 239000003270 steroid hormone Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- 210000001215 vagina Anatomy 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DK93950A DK95093D0 (da) | 1993-08-20 | 1993-08-20 | Farmaceutisk formulering indeholdende et hormon |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ271617A true NZ271617A (en) | 1996-11-26 |
Family
ID=8099329
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ271617A NZ271617A (en) | 1993-08-20 | 1994-08-19 | Oral pharmaceutical composition comprising micronized progesterone, poly ethylene glycol and a starch, cellulose pectin or tragacanth excipient |
Country Status (17)
| Country | Link |
|---|---|
| EP (1) | EP0789560A1 (da) |
| JP (1) | JPH09501682A (da) |
| KR (1) | KR960703570A (da) |
| CN (1) | CN1132478A (da) |
| AU (1) | AU7530594A (da) |
| BR (1) | BR9407306A (da) |
| CA (1) | CA2169840A1 (da) |
| CZ (1) | CZ42596A3 (da) |
| DK (1) | DK95093D0 (da) |
| FI (1) | FI960749A0 (da) |
| HU (1) | HUT74167A (da) |
| LT (1) | LT4043B (da) |
| NO (1) | NO960653D0 (da) |
| NZ (1) | NZ271617A (da) |
| PL (1) | PL313113A1 (da) |
| SK (1) | SK19396A3 (da) |
| WO (1) | WO1995005807A1 (da) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2772617B1 (fr) * | 1997-12-19 | 2001-03-09 | Besins Iscovesco Lab | Comprime de progesterone et son procede de preparation |
| FR2775599B1 (fr) | 1998-03-09 | 2001-08-17 | Besins Iscovesco Lab | Composition pharmaceutique a base de progesterone naturelle de synthese et d'oestradiol et son procede de preparation |
| GB2339114B (en) * | 1998-06-30 | 2003-03-05 | Ericsson Telefon Ab L M | Secure messaging in mobile telephones |
| IL127129A (en) * | 1998-11-18 | 2004-06-01 | Ferring Bv | Method for preparation of progesterone tablets for vaginal delivery and tablets so prepared |
| BR0014159A (pt) * | 1999-08-31 | 2002-05-07 | Schering Ag | Combinação farmacêutica de etinilestradiol e drospirenona para uso como um anticoncepcional |
| US6544553B1 (en) * | 1999-12-28 | 2003-04-08 | Watson Pharmaceuticals, Inc. | Dosage forms and methods for oral delivery of progesterone |
| FI20002768L (fi) * | 2000-12-18 | 2002-06-19 | Licentia Oy | Enteropäällysteisiä lääkekoostumuksia ja niiden valmistus |
| WO2003077923A1 (en) * | 2002-03-14 | 2003-09-25 | Watson Pharmaceuticals, Inc. | Progesterone oral drug delivery system |
| BRPI0409860A (pt) * | 2003-04-29 | 2006-05-16 | Akzo Nobel Nv | processo de solidificação anti-solvente |
| CN101166521A (zh) | 2005-04-28 | 2008-04-23 | 惠氏公司 | 通过湿制粒法制备包含微粒化他那普戈特的组合物 |
| AT12800U1 (de) * | 2007-11-05 | 2012-11-15 | Bayer Schering Pharma Ag | Pharmazeutisches Präparat zur Verwendung bei der oralen Kontrazeption von Frauen mit Laktoseintoleranz |
| US9375437B2 (en) | 2010-06-18 | 2016-06-28 | Lipocine Inc. | Progesterone containing oral dosage forms and kits |
| US20110312928A1 (en) * | 2010-06-18 | 2011-12-22 | Lipocine Inc. | Progesterone Containing Oral Dosage Forms and Related Methods |
| US8951996B2 (en) | 2011-07-28 | 2015-02-10 | Lipocine Inc. | 17-hydroxyprogesterone ester-containing oral compositions and related methods |
| US9301920B2 (en) | 2012-06-18 | 2016-04-05 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
| EP2782584B1 (en) | 2011-11-23 | 2021-06-09 | TherapeuticsMD, Inc. | Natural combination hormone replacement formulations and therapies |
| US10806740B2 (en) | 2012-06-18 | 2020-10-20 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
| US10806697B2 (en) | 2012-12-21 | 2020-10-20 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US9180091B2 (en) | 2012-12-21 | 2015-11-10 | Therapeuticsmd, Inc. | Soluble estradiol capsule for vaginal insertion |
| US10537581B2 (en) | 2012-12-21 | 2020-01-21 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US11266661B2 (en) | 2012-12-21 | 2022-03-08 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| AR100562A1 (es) | 2014-05-22 | 2016-10-12 | Therapeuticsmd Inc | Composición farmacéutica de estradiol y progesterona para terapia de reemplazo hormonal |
| JP2018522854A (ja) | 2015-06-22 | 2018-08-16 | リポカイン インコーポレーテッド | １７−ヒドロキシプロゲステロンエステル含有経口組成物及び関連方法 |
| US11633405B2 (en) | 2020-02-07 | 2023-04-25 | Therapeuticsmd, Inc. | Steroid hormone pharmaceutical formulations |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3862311A (en) * | 1971-04-12 | 1975-01-21 | Ciba Geigy Corp | Novel method of enhancing progestational endometrial proliferation with progesterone |
| FR2408345A1 (fr) | 1976-11-30 | 1979-06-08 | Besins Jean Louis | Nouvelle composition a action anti-conceptionnelle |
| GB2091552A (en) | 1980-09-09 | 1982-08-04 | Carnrick G W Ltd | Use of progesterone for the treatment of post-menopausal women |
| US4963540A (en) * | 1986-04-16 | 1990-10-16 | Maxson Wayne S | Method for treatment of premenstrual syndrome |
| US5084277A (en) | 1988-08-30 | 1992-01-28 | Greco John C | Vaginal progesterone tablet |
| US5116619A (en) | 1988-08-30 | 1992-05-26 | Lee Roy Morgan | Vaginal progesterone tablet |
| WO1990008537A1 (en) * | 1989-02-06 | 1990-08-09 | Abbott Laboratories | Pharmaceutical compositions for oral administration |
| US5223268A (en) * | 1991-05-16 | 1993-06-29 | Sterling Drug, Inc. | Low solubility drug-coated bead compositions |
-
1993
- 1993-08-20 DK DK93950A patent/DK95093D0/da not_active Application Discontinuation
-
1994
- 1994-08-19 NZ NZ271617A patent/NZ271617A/en unknown
- 1994-08-19 BR BR9407306A patent/BR9407306A/pt not_active Application Discontinuation
- 1994-08-19 WO PCT/DK1994/000310 patent/WO1995005807A1/en not_active Application Discontinuation
- 1994-08-19 EP EP94925355A patent/EP0789560A1/en not_active Withdrawn
- 1994-08-19 HU HU9600376A patent/HUT74167A/hu unknown
- 1994-08-19 CN CN94193573A patent/CN1132478A/zh active Pending
- 1994-08-19 KR KR1019960700847A patent/KR960703570A/ko not_active Withdrawn
- 1994-08-19 CA CA002169840A patent/CA2169840A1/en not_active Abandoned
- 1994-08-19 PL PL94313113A patent/PL313113A1/xx unknown
- 1994-08-19 JP JP7507271A patent/JPH09501682A/ja active Pending
- 1994-08-19 CZ CZ96425A patent/CZ42596A3/cs unknown
- 1994-08-19 SK SK193-96A patent/SK19396A3/sk unknown
- 1994-08-19 AU AU75305/94A patent/AU7530594A/en not_active Abandoned
-
1996
- 1996-02-15 LT LT96-010A patent/LT4043B/lt not_active IP Right Cessation
- 1996-02-19 NO NO960653A patent/NO960653D0/no unknown
- 1996-02-19 FI FI960749A patent/FI960749A0/fi not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| PL313113A1 (en) | 1996-06-10 |
| WO1995005807A1 (en) | 1995-03-02 |
| AU7530594A (en) | 1995-03-21 |
| DK95093D0 (da) | 1993-08-20 |
| CZ42596A3 (en) | 1996-06-12 |
| SK19396A3 (en) | 1997-03-05 |
| KR960703570A (ko) | 1996-08-31 |
| CA2169840A1 (en) | 1995-03-02 |
| LT96010A (da) | 1996-06-25 |
| NO960653L (no) | 1996-02-19 |
| HU9600376D0 (en) | 1996-04-29 |
| HUT74167A (en) | 1996-11-28 |
| CN1132478A (zh) | 1996-10-02 |
| LT4043B (en) | 1996-09-25 |
| JPH09501682A (ja) | 1997-02-18 |
| BR9407306A (pt) | 1996-10-08 |
| NO960653D0 (no) | 1996-02-19 |
| EP0789560A1 (en) | 1997-08-20 |
| FI960749L (fi) | 1996-02-19 |
| FI960749A0 (fi) | 1996-02-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NZ271617A (en) | Oral pharmaceutical composition comprising micronized progesterone, poly ethylene glycol and a starch, cellulose pectin or tragacanth excipient | |
| RU2479306C2 (ru) | Фармацевтическая композиция, содержащая тетрагидрофолиевую кислоту | |
| CN1273141C (zh) | 包含17β－雌二醇－3－低级链烷酸酯的口服药品和制备方法 | |
| KR102539030B1 (ko) | 드로스피레논을 포함하는 약학적 조성물 및 피임용 키트 | |
| AU2013326866A1 (en) | Progesterone containing oral dosage forms and kits | |
| AU2021244791B2 (en) | Pharmaceutical compositions, method of making and method of using thereof | |
| US5891867A (en) | Hormonal medicaments and their use for the correction of oestrogenic deficiencies | |
| JP2000515888A (ja) | 経口避妊薬 | |
| RU2258512C2 (ru) | Противозачаточное лекарственное средство на основе гестагена и эстрогена и способ его получения | |
| US20210308155A1 (en) | Pharmaceutical compositions, method of making and method of using thereof | |
| US20030176404A1 (en) | Progestogen-anti-progestogen regimens | |
| WO2005117899A1 (en) | Pharmaceutical composition comprising tibolone and process for procuding the same | |
| US11679114B2 (en) | Progestogen-only oral contraception | |
| EP1178807B1 (en) | Use of org 33245 in combined intermittent hormone therapy and contraception | |
| CN1950092A (zh) | 对延长的激素避孕方案中突破性出血的控制 | |
| EP1909799A1 (en) | Oral contraception with trimegestone |